Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month
Bausch Health (NYSE/TSX: BHC) and its gastroenterology unit Salix Pharmaceuticals have launched 'IBS Symptoms Aren't Black and White: Living in the Gray,' a storytelling campaign for IBS Awareness Month in April 2025.
The initiative aims to highlight the complexities of Irritable Bowel Syndrome (IBS), a condition affecting up to 10% of the global population. The campaign will share patient stories on LinkedIn, focusing on how IBS impacts physical, emotional, social, and professional well-being.
Salix has partnered with the International Foundation for Gastrointestinal Disorders (IFFGD) to reduce stigma and encourage open discussions about IBS symptoms, including diarrhea, difficult bowel movements, abdominal pain, bloating, and urgency. The campaign seeks to empower patients to seek appropriate care and improve how IBS is perceived, diagnosed, and treated.
Bausch Health (NYSE/TSX: BHC) e la sua unità di gastroenterologia Salix Pharmaceuticals hanno lanciato la campagna di narrazione 'I Sintomi dell'IBS Non Sono Bianco e Nero: Vivere nel Grigio', in occasione del Mese di Sensibilizzazione sull'IBS ad aprile 2025.
L'iniziativa mira a mettere in evidenza le complessità della Sindrome dell'Intestino Irritabile (IBS), una condizione che colpisce fino al 10% della popolazione globale. La campagna condividerà storie di pazienti su LinkedIn, concentrandosi su come l'IBS influisce sul benessere fisico, emotivo, sociale e professionale.
Salix ha collaborato con la Fondazione Internazionale per i Disturbi Gastrointestinali (IFFGD) per ridurre lo stigma e incoraggiare discussioni aperte sui sintomi dell'IBS, tra cui diarrea, difficoltà nei movimenti intestinali, dolore addominale, gonfiore e urgenza. La campagna si propone di dare potere ai pazienti affinché cerchino le cure appropriate e migliorare la percezione, la diagnosi e il trattamento dell'IBS.
Bausch Health (NYSE/TSX: BHC) y su unidad de gastroenterología Salix Pharmaceuticals han lanzado la campaña de narración 'Los Síntomas del SII No Son Blancos ni Negros: Viviendo en el Gris', con motivo del Mes de Concienciación sobre el SII en abril de 2025.
La iniciativa tiene como objetivo resaltar las complejidades del Síndrome del Intestino Irritable (SII), una condición que afecta hasta el 10% de la población mundial. La campaña compartirá historias de pacientes en LinkedIn, centrándose en cómo el SII impacta el bienestar físico, emocional, social y profesional.
Salix se ha asociado con la Fundación Internacional para los Trastornos Gastrointestinales (IFFGD) para reducir el estigma y fomentar discusiones abiertas sobre los síntomas del SII, incluidos diarrea, dificultad para evacuar, dolor abdominal, hinchazón y urgencia. La campaña busca empoderar a los pacientes para que busquen la atención adecuada y mejorar la forma en que se percibe, diagnostica y trata el SII.
바우쉬 헬스 (NYSE/TSX: BHC)와 그 위장병학 부서인 살릭스 제약이 2025년 4월 IBS 인식의 달을 맞아 'IBS 증상은 흑백이 아니다: 회색에서 살기'라는 스토리텔링 캠페인을 시작했습니다.
이 이니셔티브는 전 세계 인구의 최대 10%에 영향을 미치는 과민성 장 증후군(IBS)의 복잡성을 강조하는 것을 목표로 하고 있습니다. 캠페인은 LinkedIn에서 환자 이야기를 공유하며, IBS가 신체적, 정서적, 사회적 및 직업적 웰빙에 미치는 영향을 집중적으로 다룰 것입니다.
살릭스는 국제 위장 질환 재단(IFFGD)와 협력하여 IBS 증상에 대한 낙인을 줄이고, 설사, 배변 어려움, 복통, 팽만감 및 긴급성을 포함한 증상에 대해 열린 논의를 장려하고자 합니다. 이 캠페인은 환자들이 적절한 치료를 받을 수 있도록 힘을 주고, IBS에 대한 인식, 진단 및 치료 방식을 개선하는 것을 목표로 하고 있습니다.
Bausch Health (NYSE/TSX: BHC) et sa division gastro-entérologie Salix Pharmaceuticals ont lancé la campagne de narration 'Les Symptômes du SII Ne Sont Pas Blancs ni Noirs : Vivre dans le Gris', à l'occasion du Mois de Sensibilisation au SII en avril 2025.
Cette initiative vise à mettre en lumière les complexités du Syndrome de l'Intestin Irritable (SII), une condition touchant jusqu'à 10 % de la population mondiale. La campagne partagera des histoires de patients sur LinkedIn, en se concentrant sur l'impact du SII sur le bien-être physique, émotionnel, social et professionnel.
Salix s'est associé à la Fondation Internationale pour les Troubles Gastro-Intestinaux (IFFGD) pour réduire la stigmatisation et encourager des discussions ouvertes sur les symptômes du SII, y compris la diarrhée, les difficultés de transit intestinal, les douleurs abdominales, les ballonnements et l'urgence. La campagne vise à responsabiliser les patients pour qu'ils recherchent des soins appropriés et à améliorer la perception, le diagnostic et le traitement du SII.
Bausch Health (NYSE/TSX: BHC) und ihre Gastroenterologie-Einheit Salix Pharmaceuticals haben die Erzählkampagne 'IBS-Symptome sind nicht schwarz und weiß: Leben im Grauen' zum Monat der IBS-Aufklärung im April 2025 ins Leben gerufen.
Die Initiative zielt darauf ab, die Komplexität des Reizdarmsyndroms (IBS) hervorzuheben, einer Erkrankung, die bis zu 10 % der Weltbevölkerung betrifft. Die Kampagne wird Patientenberichte auf LinkedIn teilen, die sich darauf konzentrieren, wie IBS das körperliche, emotionale, soziale und berufliche Wohlbefinden beeinflusst.
Salix hat sich mit der International Foundation for Gastrointestinal Disorders (IFFGD) zusammengeschlossen, um Stigmatisierung abzubauen und offene Diskussionen über IBS-Symptome wie Durchfall, Schwierigkeiten beim Stuhlgang, Bauchschmerzen, Blähungen und Dringlichkeit zu fördern. Die Kampagne zielt darauf ab, Patienten zu ermutigen, angemessene medizinische Hilfe in Anspruch zu nehmen und die Wahrnehmung, Diagnose und Behandlung von IBS zu verbessern.
- None.
- None.
Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, diagnosed and treated.
LAVAL, QC / ACCESS Newswire / April 2, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the launch of IBS Symptoms Aren't Black and White: Living in the Gray, an authentic storytelling campaign that addresses the complexities of living with irritable bowel syndrome (IBS). Throughout April, which is IBS Awareness Month, Salix will be sharing patient stories on LinkedIn, highlighting the unique journeys of individuals living with IBS.
Irritable bowel syndrome is more than just a common condition that affects up to an estimated
"We recognize that every patient's experience is unique and has the potential to inspire others in the IBS community to seek the care they deserve," said Nicola Kayel, Senior Vice President, Marketing, Salix. "Our campaign, IBS Symptoms Aren't Black & White: Living in the Gray, underscores our ongoing commitment to supporting patients by amplifying their voices to raise visibility, build a community of empowered individuals and destigmatize the narrative that surrounds this condition."
Many people with IBS agree that their symptoms, such as diarrhea and hard to pass bowel movements, can be hard to talk about, and as a result, unresolved symptoms cause the burden of IBS to persist.2 Patient advocacy group, the International Foundation for Gastrointestinal Disorders (IFFGD), recognizes this obstacle and is partnering with Salix to generate conversation and share authentic stories. By normalizing open and honest discussions about IBS and reducing stigma, Salix and IFFGD hope to motivate patients to talk to their healthcare providers about the full range of their IBS symptoms, including less obvious experiences like abdominal pain, bloating and urgency.
President of IFFGD, Ceciel T. Rooker, stated, "At IFFGD, we are committed to broadening patient understanding of GI disorders like IBS. We are proud to support Salix in their effort to illuminate real patient stories to help raise visibility of the authentic patient experience and the multi-faceted nature of IBS symptoms. We believe it will encourage patients to speak up about their symptoms and ultimately receive appropriate care for their condition."
Click here to read about real patients' experiences on Salix Pharmaceuticals' LinkedIn.
##
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.
References
Mayo Clinic. (2023). Irritable Bowel Syndrome (IBS). Retrieved from https://www.mayoclinic.org/diseases-conditions/irritable-bowel-syndrome/symptoms-causes/syc-20360016
International Foundation for Functional Gastrointestinal Disorders (IFFGD). (2024) IBS Facts and Statistics. AboutIBS.org. https://aboutibs.org/what-is-ibs/facts-about-ibs/.
©2025 Salix Pharmaceuticals or its affiliates.
Investor Contact: |
| Media Contact: |
SOURCE: Bausch Health Companies Inc.
View the original press release on ACCESS Newswire
FAQ
What is the purpose of Bausch Health's new IBS awareness campaign in April 2025?
How many people are affected by IBS according to BHC's campaign?
What partnership has Salix Pharmaceuticals formed for IBS Awareness Month 2025?
What symptoms of IBS does BHC's awareness campaign address?
Where can investors find patient stories from BHC's IBS awareness campaign?
